Madrigal Pharmaceuticals
499,71 $Variación respecto al cierre anterior: −0,84 %Variación absoluta: −4,25 $
Perfil de la empresa
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Descripción disponible en inglés.
Datos societarios
- Sector
- Salud
- Industria
- Biotechnology
- País
- Estados Unidos
- Sede
- 1001 Conshohocken State Road, 19428, West Conshohocken
- Empleados
- 915
- Cotización
- MDGL · NASDAQ
- Divisa
- USD
- Sitio web
- madrigalpharma.com